The Questcor Strikes Back
- Posted by Danny
- on February 23rd, 2012
After taking a big hit from The StreetSweeper last month, QCOR retaliates with a strong QFOUR.
Are the allegations of impropriety and crude sales tactics legit? I don’t know, but things sure as hell smell fishy after The StreetSweeper leveled a body blow to Questcor Pharmaceuticals ($QCOR) and its investors back on January 11, 2012.
At that time they told their followers that in the next week they would be releasing the first in a two-part investigative report on QCOR, and that they had already “sold 80,599 shares of QCOR short at an average price of $41.46 a share in anticipation of a future decline in the stock price.”
Well the stock immediately tanked after that statement. Talk about good timing! Here’s what they finally reported.
In response, QCOR basically said they didn’t know who the funk StreetSweeper was or what they were up to, but answered their questions nevertheless. It’s laid out here.
Even better than responding to their inquiries though, QCOR unleashed a most awesome Q4 report last night that beat the consensus on both EPS and revs. Full year numbers kicked ass too.
Here’s the digits for Q4 YoY:
- Sales +158%
- Net income +292%
- Acthar vial shipments +100%
- Filled Rx’s for MS +167%
Full year 2011:
- Sales +90%
- Net income +127%
- Acthar vial shipments +60%
- Filled Rx’s for MS +155%
The StockTwits stream was abuzz after earnings, with the majority of the community seemingly on QCOR’s side of the showdown. Check out @bbolan1‘s awesome tweets as he followed their conference call.
Ranked #21 in the BeanScreen, we don’t own any QCOR shares right now, but we’ve been watching them very closely as their fundamentals appear to be pretty strong at this time.
There is a part of me that just wants to give StreetSweeper the finger and buy a bunch of shares in QCOR, but as stated above, we just don’t know for sure if the allegations have any merit or not. I hate unknowns like this…better to wait and let the dust settle.
BRLI has almost doubled off its lows since getting “swept”.
sources: Questcor Earnings Beat Street; Stock Rises Late – Investors.com
Questcor Reports Fourth Quarter and Full Year 2011 Financial Results – Y! Finance
Questcor Pharmaceuticals Responds to Questions From Investor Blog – Y! Finance
Questcor: A Bold Strategy Threatened by the Fine Print? – TheStreetSweeper
Is Bio-Reference Laboratories As Healthy As It Seems? – Seeking Alpha
disclosure: we do not own any shares in QCOR or BRLI at this time
The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment. I or my affiliates may hold positions or other interests in securities mentioned in the Blog, please see my Disclaimer page for my full disclaimer.blog comments powered by Disqus
Daniel Miller and Jason Robinson are self taught investors based in Daphne, Alabama, and are the co-founders of the WallStreetBean. Neither one of them are professional investors - just two regular guys who want to share their investing ideas and thoughts with others. More
- BeanScreen for December 1, 2013
- The Mother of All Analogs (Update)
- Inter Parfums Declares Special Dividend
- Atwood Reports Q4 and Fiscal 2013
- Qualcomm Earnings Recap
- CF Misses Top Line, Beats on the Bottom
- BeanScreen for November 1, 2013
- United Therapeutics Reports Q3
- Alexion Q3 Beats on Top and Bottom
- Myriad Aims to Protect its Remaining Patents